Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.
Clinical trial NCT04526197 · COMPLETED
Trial details
- NCT number
- NCT04526197
- Sponsor
- Alexion Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-07
- Primary completion
- 2020-11-03
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.